- Conditions
- Hepatitis
- Interventions
- hepatitis B vaccine
- Biological
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 13 Years to 16 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Anchorage, Alaska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 1,029
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections
- Interventions
- ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 1997
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • St Louis, Missouri • Rochester, New York
- Conditions
- Osteoarthritis, Knee
- Interventions
- Sprifermin, Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 2
- States / cities
- Lakewood, Colorado • Baltimore, Maryland
- Conditions
- Plague Vaccine
- Interventions
- rF1V vaccine (with Adjuvant), rF1V vaccine (without Adjuvant)
- Biological
- Lead sponsor
- DynPort Vaccine Company LLC, A GDIT Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 402 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 11
- States / cities
- San Francisco, California • Santa Ana, California • Lenexa, Kansas + 8 more
- Conditions
- Burns
- Interventions
- Recombinant Factor VIIa, Placebo
- Drug
- Lead sponsor
- United States Army Institute of Surgical Research
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Fort Sam Houston, Texas
- Conditions
- Von Willebrand Disease (VWD)
- Interventions
- rVWF, rFVIII
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Aurora, Colorado • Gainesville, Florida + 5 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- sargramostim, topotecan hydrochloride
- Biological · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2002
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Nipah Virus Infection
- Interventions
- PHV02, Lactated Ringer's
- Biological
- Lead sponsor
- Public Health Vaccines LLC
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Anaheim, California • Hollywood, Florida • Salt Lake City, Utah
- Conditions
- Anemia
- Interventions
- PROCRIT, Placebo
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Orange, California • Santa Barbara, California + 18 more
- Conditions
- Acute Kidney Injury
- Interventions
- erythropoietin, saline
- Drug
- Lead sponsor
- North Texas Veterans Healthcare System
- Federal
- Eligibility
- 21 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- HIV Infections
- Interventions
- CD4 Antigens
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- South San Francisco, California
- Conditions
- Healthy
- Interventions
- MEDI-560, Placebo
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 1 Month to 11 Months
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 23
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Madera, California + 20 more
- Conditions
- Melanoma, Carcinoma, Renal Cell
- Interventions
- rh IL-15
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV Infections
- Interventions
- rgp120/HIV-1MN, rgp120/HIV-1 SF-2
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 16 Years to 60 Years
- Enrollment
- 296 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 1997
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 3 more
- Conditions
- Phase 1 Pharmacodynamic Study
- Interventions
- Oral rsCT tablet, Oral Placebo Tablet, Fortical (rsCT) nasal spray
- Drug
- Lead sponsor
- Tarsa Therapeutics, Inc.
- Industry
- Eligibility
- 45 Years to 70 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Bleeding Disorder
- Interventions
- Recombinant von Willebrand Factor
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Breast Cancer
- Interventions
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, sargramostim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Epstein Barr Virus (EBV) Infection
- Interventions
- MVA-BN-EBV, Placebo
- Biological
- Lead sponsor
- Bavarian Nordic
- Industry
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- recombinant human endostatin
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Kaposi's Sarcoma, HIV Infections, HIV Seronegativity
- Interventions
- Bevacizumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Influenza
- Interventions
- Flublok® Quadrivalent Influenza Virus Vaccine, Fluarix Quadrivalent® Influenza Virus Vaccine
- Biological
- Lead sponsor
- Protein Sciences Corporation
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 219 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Auburn, Maine
- Conditions
- Sarcoma, Kaposi, HIV Infections
- Interventions
- Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Zidovudine, Sargramostim
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 14 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1993
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Boston, Massachusetts • Buffalo, New York + 1 more
- Conditions
- HIV Infections
- Interventions
- Ad5.ENVA.48 HIV-1 vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sanfilippo Syndrome Type A
- Interventions
- GC1130A
- Drug
- Lead sponsor
- GC Biopharma Corp
- Industry
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Oakland, California • Minneapolis, Minnesota